That followed approval by the FDA in January, and the Brazilian regulator ANVISA in July.

Further Phase I studies of ALX-0171 are planned, and if successful the product will be moved into a pediatric Phase II trial.

Overall, if we can get greater commercial returns back into research, the whole ecosystem should improve."

By Nuala Moran Staff Writer LONDON – Wellington Partners announced the first closing of its fourth life science fund at €70 million (US$90.8 million), putting the firm well on to the way to its final target of €120 million and of achieving a significant increase over its third life science fund, which raised €78 million

AAA took ownership of Lutathera as recently as 2010, when it acquired Biosynthema Inc., of St Louis.

Overall, Cren said, "the aim is that when a pharma company wants to do a discovery program involving nuclear receptors and the control of transcription, they think of Inventiva."

However, the basic research continues to be carried out in Singapore by co-founder Dieter Trau and there is "lasting bridge" between the two.

However, the basic research continues to be carried out in Singapore by co-founder Dieter Trau and there is "lasting bridge" between the two.

Oncolytic viruses are very much on the cusp of being an interesting sector, both clinically and commercially."

community," he said.

community," he said.

Symphogen has developed platform technologies for doing that, and Dreyer said that while Sym-004 targets two epitopes, future products will be aimed at multiple targets.

there is great expertise when comes to academic labs."

Wischik declined to say how much more money has now been raised to fund the two Phase III trials.

Wischik declined to say how much more money has now been raised to fund the two Phase III trials.

Symphogen has developed platform technologies for doing that, and Dreyer said that while Sym-004 targets two epitopes, future products will be aimed at multiple targets.

By Nuala Moran Staff Writer LONDON – Genmab A/S signed up a "dream partner" last week for its anti-CD38 monoclonal antibody daratumumab, agreeing a worldwide commercialization deal with Janssen Biotech Inc., with a total potential value of more than $1.1 billion, of which $135 million is to be paid up front

His hope is that the proposal will find its way into the government's annual budget in March 2013.

The acquisition of the Minnesota facility for $480 million in 2008 was also seen as a serious error. (See BioWorld International, June 16, 2010.)